Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2020-04, Vol.34 (4), p.1182-1186
Hauptverfasser:	Kubasch, Anne Sophie, Schulze, Freya, Giagounidis, Aristoteles, Götze, Katharina S., Krönke, Jan, Sockel, Katja, Middeke, Jan Moritz, Chermat, Fatiha, Gloaguen, Silke, Puttrich, Martin, Weigt, Carmen, William, Doreen, Fenaux, Pierre, Schlenk, Richard F., Thiede, Christian, Stasik, Sebastian, Mies, Anna, Adès, Lionel, Oelschlägel, Uta, Platzbecker, Uwe
Format:	Artikel
Sprache:	eng
Schlagworte:	13/1 13/100 13/21 13/31 13/95 38/77 631/67/1059/2325 631/67/1059/2326 631/67/1990/1673 631/67/1990/283/1897 631/67/580/1884/2323 Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibody-Dependent Cell Cytotoxicity Antimetabolites, Antineoplastic - adverse effects Antimitotic agents Antineoplastic agents Azacitidine - adverse effects Cancer Research Cellular proteins Critical Care Medicine Development and progression Drug Resistance, Neoplasm - drug effects Drug therapy Drug-Related Side Effects and Adverse Reactions - diagnosis Drug-Related Side Effects and Adverse Reactions - etiology Female Follow-Up Studies Genetic aspects Geriatrics Health aspects Hematology Humans Intensive Interleukin-3 Receptor alpha Subunit - antagonists & inhibitors Interleukin-3 Receptor alpha Subunit - immunology Internal Medicine Letter Male Medicine Medicine & Public Health Myelodysplastic syndromes Myelodysplastic Syndromes - drug therapy Myelodysplastic Syndromes - immunology Myelodysplastic Syndromes - pathology Oncology Patient outcomes Prognosis Survival Rate Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:
ISSN:	0887-6924 1476-5551
DOI:	10.1038/s41375-019-0645-z